EICHOR
● Terminated
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
Condition: Schizophrenia · Sponsor: SyneuRx International (Taiwan) Corp
About this study
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (23)
| Harmonex Neuroscience Research | Dothan, Alabama, United States | — |
| CiTrials | Bellflower, California, United States | — |
| Renew Behavioral Health, Inc. | Long Beach, California, United States | — |
| CiTrials | Riverside, California, United States | — |
| Institute of Living/Hartford Hospital | Hartford, Connecticut, United States | — |
| Children's National Health System | Washington D.C., District of Columbia, United States | — |
| Premier Clinical Research Institute | Miami, Florida, United States | — |
| Medical Research Group of Central Florida | Orange City, Florida, United States | — |
| Atlanta Center for Medical Research | Atlanta, Georgia, United States | — |
| John Hopkins University - Hugo W Moser Research Institute at Kennedy Krieger Inc. | Baltimore, Maryland, United States | — |
| University of Massachusetts Medical School - Psychiatry Department | Worcester, Massachusetts, United States | — |
| Michigan Clinical Research Institute | Ann Arbor, Michigan, United States | — |
+ 11 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01908192